Evolving concepts of selective estrogen receptor action: From basic science to clinical applications

Trends in Endocrinology and Metabolism

Volumn 10, Issue 8, 1999, Pages 299-300

  Smith, Carolyn L ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; LIGAND; NUCLEAR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR;

CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; NASA DISCIPLINE CELL BIOLOGY; NON-NASA CENTER; REVIEW;

NASA DISCIPLINE CELL BIOLOGY; NON-NASA CENTER;

DRUG DESIGN; ESTROGEN ANTAGONISTS; LIGANDS; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 0033205971     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(99)00183-6     Document Type: Review

References (14)

1. Jordan, V.C. (1992) The Strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70 (Suppl. 4), 977-982
2. Love, R.R. et al. (1992) Effect of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326, 852-856
3. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L. and Cronin, W.M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the national surgical adjuvant breast and bowel project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537
4. Tzukerman, M.T. et al. (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8, 21-30
5. Smith, C.L., Nawaz, Z. and O'Malley, B.W. (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxy-tamoxifen. Mol. Endocrinol. 11, 657-666
6. Beekman, J.M., Allan, G.F., Tsai, S.Y., Tsai, M-J. and O'Malley, B.W. (1993) Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 7, 1266-1274
7. McDonnell, D.P., Clemm, D.L., Hermann, T., Goldman, M.E. and Pike, J.W. (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9, 659-669
8. Martin, P.M., Bererthoisis, Y. and Jensen, E.V. (1988) Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 85, 2533-2537
9. Shibata, H. et al. (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 52, 141-164
10. Glass, C.K., Rose, D.W. and Rosenfeld, M.G. (1997) Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9, 222-232
11. Jackson, T.A., Richer, J.K., Bain, D.L., Takimoto, G.S., Tung, L. and Horwitz, K.B. (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol. 11, 693-705
12. Lavinsky, R.M. et al. (1998) Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. U. S. A. 95, 2920-2925
13. Brzozowski, A.M. et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758
14. Shiau, A.K. et al. (1998) The structural basis of estrogen reecptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937